Compass therapeutics announces poster presentations at the cholangiocarcinoma foundation 2024 annual conference

Boston, april 12, 2024 (globe newswire) -- compass therapeutics, inc. (nasdaq: cmpx), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced poster presentations on ctx-009, the company's bispecific dll4/vegf-a antibody, at the cholangiocarcinoma foundation (ccf) 2024 annual conference to be held at the salt palace convention center in salt lake city, utah from april 17–19, 2024.
CMPX Ratings Summary
CMPX Quant Ranking